A Phase 1 interventional study of DOR/ISL in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to doravirine (DOR) and islatravir (ISL) in a healthy lactating female's body over time. Researchers want to learn if DOR and ISL are in breast milk.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive DOR/ISL as an oral fixed-dose combination tablet once daily on Days 1 to 7.
Drug: DOR/ISL
Drug pages: Doravirine · Islatravir
Oral tablet
Also known as: MK-8591A
Cumulative Amount of DOR Excreted in Breast Milk From 0 to 24 Hours (Ae0-24hrs)
Breast milk samples will be collected to determine the Ae0-24hrs after administration of DOR.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Body Weight Normalized Infant Theoretical Dose of DOR
Breast milk samples will be collected to calculate the theoretical daily (24 hour) infant dose of DOR as normalized by participant-reported infant body weight.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Relative Infant Theoretical Dose of DOR
Breast milk samples will be collected to calculate the theoretical daily (24 hour) infant dose of DOR relative to the maternal dose.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Cumulative Amount of Total ISL Excreted in Breast Milk From 0 to 24 Hours (Ae0-24hrs)
Breast milk samples will be collected to determine the Ae0-24hrs after administration of total ISL.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Body Weight Normalized Infant Theoretical Dose of ISL
Breast milk samples will be collected to calculate the theoretical daily (24 hour) infant dose of ISL as normalized by participant-reported infant body weight.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Relative Infant Theoretical Dose of ISL
Breast milk samples will be collected to calculate the theoretical daily (24 hour) infant dose of ISL relative to the maternal dose.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24hrs) of DOR in Breast Milk
Breast milk samples will be collected to determine the AUC0-24hrs of DOR.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Maximum Concentration (Cmax) of DOR in Breast Milk
Breast milk samples will be collected to determine the Cmax of DOR.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Time to Maximum Concentration (Tmax) of DOR in Breast Milk
Breast milk samples will be collected to determine the Tmax of DOR
Time frame: Predose and at designated timepoints up to 24 hours postdose
AUC0-24hrs of Total ISL in Breast Milk
Breast milk samples will be collected to determine the AUC0-24hrs of total ISL.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Cmax of Total ISL in Breast Milk
Breast milk samples will be collected to determine the Cmax of total ISL.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Tmax of Total ISL in Breast Milk
Breast milk samples will be collected to determine the Tmax of total ISL.
Time frame: Predose and at designated timepoints up to 24 hours postdose
AUC0-24hrs of DOR in Plasma
Plasma samples will be collected to determine the AUC0-24hrs of DOR.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Cmax of DOR in Plasma
Plasma samples will be collected to determine the Cmax of DOR.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Tmax of DOR in Plasma
Plasma samples will be collected to determine the Tmax of DOR.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Concentration at 24 Hours (C24) of DOR in Plasma
Plasma samples will be collected to determine the C24 of DOR.
Time frame: Predose and at designated timepoints up to 24 hours postdose
AUC0-24hrs of ISL in Plasma
Plasma samples will be collected to determine the AUC0-24hrs of ISL.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Cmax of ISL in Plasma
Plasma samples will be collected to determine the Cmax of ISL.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Tmax of ISL in Plasma
Plasma samples will be collected to determine the Tmax of ISL.
Time frame: Predose and at designated timepoints up to 24 hours postdose
C24 of ISL in Plasma
Plasma samples will be collected to determine the C24 of ISL.
Time frame: Predose and at designated timepoints up to 24 hours postdose
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Sep 2025 to primary completion in Dec 2025, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Doravirine · Islatravir